David A Palma1,2, Timothy K Nguyen1,3, Alexander V Louie1,2,3, Richard Malthaner4, Dalilah Fortin4, George B Rodrigues1,2, Brian Yaremko1,2, Joanna Laba1,2, Keith Kwan5, Stewart Gaede2,6,7, Ting Lee2,6, Aaron Ward2,6, Andrew Warner1, Richard Inculet4. 1. Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada. 2. Department of Oncology, Western University, London, Ontario, Canada. 3. Currently with Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 4. Department of Surgery, Division of Thoracic Surgery, London Health Sciences Centre, London, Ontario, Canada. 5. Department of Pathology, Western University, London, Ontario, Canada. 6. Department of Medical Biophysics, Western University, London, Ontario, Canada. 7. Department of Physics and Engineering, Western University, London, Ontario, Canada.
Abstract
IMPORTANCE: Stereotactic ablative radiotherapy (SABR) is a standard treatment option in patients with medically inoperable early-stage non-small cell lung cancer (NSCLC), yet the pathologic complete response (pCR) rate after SABR is unknown. Neoadjuvant SABR in patients with cancer who are fit for resection has been hypothesized to improve local control and induce antitumor immune activity, potentially leading to better outcomes. OBJECTIVES: To determine the pCR rate after SABR and to assess oncologic and toxicity outcomes after a combined approach of neoadjuvant SABR followed by surgery. DESIGN, SETTING, AND PARTICIPANTS: A phase 2, single-arm trial, with patient accrual from September 30, 2014, to August 15, 2017 (median follow-up, 19 months), was performed at a tertiary academic cancer center. Patients 18 years or older with T1T2N0M0 NSCLC and good performance status, with adequate pulmonary reserve to undergo surgical resection, were studied. INTERVENTIONS: Patients underwent neoadjuvant SABR using a risk-adapted fractionation scheme followed by surgery 10 weeks later. MAIN OUTCOMES AND MEASURES: The pCR rate as determined by hematoxylin-eosin staining. RESULTS: Forty patients (mean [SD] age, 68 [8] years; 23 [58%] female) were enrolled. Thirty-five patients underwent surgery and were evaluable for the primary end point. The pCR rate was 60% (95% CI, 44%-76%). The 30- and 90-day postoperative mortality rates were both 0%. Grade 3 or 4 toxic effects occurred in 7 patients (18%). In patients receiving surgery, 2-year overall survival was 77% (95% CI, 48%-91%), local control was 100% (95% CI, not defined), regional control was 53% (95% CI, 22%-76%), and distant control was 76% (95% CI, 45%-91%). Quality of life did not decline after treatment, with no significant changes in mean Functional Assessment of Cancer Therapy for Lung-Trial Outcome Index score during the first year of follow-up. CONCLUSIONS AND RELEVANCE: The pCR rate after SABR for early-stage NSCLC was 60%, lower than hypothesized. The combined approach had toxic effects comparable to series of surgery alone, and there was no perioperative mortality. Further studies are needed to evaluate this combined approach compared with surgical resection alone. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02136355.
IMPORTANCE: Stereotactic ablative radiotherapy (SABR) is a standard treatment option in patients with medically inoperable early-stage non-small cell lung cancer (NSCLC), yet the pathologic complete response (pCR) rate after SABR is unknown. Neoadjuvant SABR in patients with cancer who are fit for resection has been hypothesized to improve local control and induce antitumor immune activity, potentially leading to better outcomes. OBJECTIVES: To determine the pCR rate after SABR and to assess oncologic and toxicity outcomes after a combined approach of neoadjuvant SABR followed by surgery. DESIGN, SETTING, AND PARTICIPANTS: A phase 2, single-arm trial, with patient accrual from September 30, 2014, to August 15, 2017 (median follow-up, 19 months), was performed at a tertiary academic cancer center. Patients 18 years or older with T1T2N0M0 NSCLC and good performance status, with adequate pulmonary reserve to undergo surgical resection, were studied. INTERVENTIONS: Patients underwent neoadjuvant SABR using a risk-adapted fractionation scheme followed by surgery 10 weeks later. MAIN OUTCOMES AND MEASURES: The pCR rate as determined by hematoxylin-eosin staining. RESULTS: Forty patients (mean [SD] age, 68 [8] years; 23 [58%] female) were enrolled. Thirty-five patients underwent surgery and were evaluable for the primary end point. The pCR rate was 60% (95% CI, 44%-76%). The 30- and 90-day postoperative mortality rates were both 0%. Grade 3 or 4 toxic effects occurred in 7 patients (18%). In patients receiving surgery, 2-year overall survival was 77% (95% CI, 48%-91%), local control was 100% (95% CI, not defined), regional control was 53% (95% CI, 22%-76%), and distant control was 76% (95% CI, 45%-91%). Quality of life did not decline after treatment, with no significant changes in mean Functional Assessment of Cancer Therapy for Lung-Trial Outcome Index score during the first year of follow-up. CONCLUSIONS AND RELEVANCE: The pCR rate after SABR for early-stage NSCLC was 60%, lower than hypothesized. The combined approach had toxic effects comparable to series of surgery alone, and there was no perioperative mortality. Further studies are needed to evaluate this combined approach compared with surgical resection alone. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02136355.
Authors: Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll Journal: N Engl J Med Date: 2018-04-16 Impact factor: 91.245
Authors: Marcelo E Facciuto; Manoj K Singh; Caroline Rochon; Jyoti Sharma; Cecilia Gimenez; Umadevi Katta; Chitti R Moorthy; Stuart Bentley-Hibbert; Manuel Rodriguez-Davalos; David C Wolf Journal: J Surg Oncol Date: 2011-09-29 Impact factor: 3.454
Authors: Kitty Huang; Sashendra Senthi; David A Palma; Femke O B Spoelstra; Andrew Warner; Ben J Slotman; Suresh Senan Journal: Radiother Oncol Date: 2013-08-13 Impact factor: 6.280
Authors: Thomas Schneider; David Reuss; Arne Warth; Philipp A Schnabel; Andreas von Deimling; Felix J F Herth; Hendrik Dienemann; Hans Hoffmann Journal: Eur J Cardiothorac Surg Date: 2010-10-18 Impact factor: 4.191
Authors: David Cella; David T Eton; Diane L Fairclough; Philip Bonomi; Anne E Heyes; Cheryl Silberman; Michael K Wolf; David H Johnson Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox Journal: Lancet Date: 2009-07-24 Impact factor: 79.321
Authors: David A Palma; Timothy K Nguyen; Keith Kwan; Stewart Gaede; Mark Landis; Richard Malthaner; Dalilah Fortin; Alexander V Louie; Eric Frechette; George B Rodrigues; Brian Yaremko; Edward Yu; A Rashid Dar; Ting-Yim Lee; Al Gratton; Andrew Warner; Aaron Ward; Richard Inculet Journal: Radiat Oncol Date: 2017-01-27 Impact factor: 3.481
Authors: D Tiberi; P Vavassis; D Nguyen; M C Guilbert; A Simon-Cloutier; P Dubé; M K Gervais; L Sideris; G Leblanc; T Hijal; M P Dufresne; M Yassa Journal: Curr Oncol Date: 2020-06-01 Impact factor: 3.677
Authors: Zhicheng Jiao; Hongming Li; Ying Xiao; Charu Aggarwal; Maya Galperin-Aizenberg; Daniel Pryma; Charles B Simone; Steven J Feigenberg; Gary D Kao; Yong Fan Journal: Int J Radiat Oncol Biol Phys Date: 2021-01-19 Impact factor: 7.038